Pfizer/AstraZeneca: part deux?
This article was originally published in Scrip
Executive Summary
So Pfizer has walked away from AstraZeneca. For those of us who earn a living from analyzing the ups and downs and ins and outs of the pharmaceutical industry, it's a bit of a relief to be honest, and that's not a comment on the relative merits of the deal. It's just … we can start writing about other things again, like drug development and innovative science! The kind of stuff that Pascal Soriot has spent the last month promising will come our way if AstraZeneca was just left alone to get on with things. We at Scrip can hardly wait for AstraZeneca to start delivering on all the promises Mr Soriot has been making to the company's investors, to the UK parliament, and to the rest of us. From key data readouts and Phase III starts in short term, to numerous new product launches and a return to growth in the medium term, and potential revenues of $45bn in the long term. Heady stuff.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.